Quercetin in Coronary Artery By-pass Surgery
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT04907253
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT04907253
-
- Other papers using this trial's data
- Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT04907253. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-04 (actual); primary completion 2023-12-01 (actual). Results posted on 2026-04-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Quercetin in Coronary Artery By-pass Surgery
- Acronym
- Q-CABG
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Quercetin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Montreal Heart Institute
Record details
- Record id
cardio:ct-nct04907253- Content hash
7b32af5844baaab1c7a06c3ca0ca4fb76787a33e6cbef132b275f2cd91af0516